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Abstract
Background: Although some studies examined the association between shared decision-making (SDM) and type
of breast cancer surgery received, it is little known how treatment decisions might be shaped by the information
provided by physicians. The purpose of this study was to identify the associations between shared decision making
(SDM) and surgical treatment received.
Methods: Questionnaires on SDM were administered to 1,893 women undergoing primary curative surgery for
newly diagnosed stage 0-II localized breast cancer at five hospitals in Korea. Questions included being informed on
treatment options and the patient’s own opinion in decision-making.
Results: Patients more likely to undergo mastectomy were those whose opinions were respected in treatment
decisions (adjusted odds ratio, aOR), 1.40; 95% confidence interval (CI), 1.14-1.72) and who were informed on
chemotherapy (aOR, 2.57; CI, 2.20-3.01) or hormone therapy (aOR, 2.03; CI, 1.77-2.32). In contrast, patients less likely
to undergo mastectomy were those who were more informed on breast surgery options (aOR, 0.34; CI, 0.27-0.42).
In patients diagnosed with stage 0-IIa cancer, clinical factors and the provision of information on treatment by the
doctor were associated with treatment decisions. In patients diagnosed with stage IIb cancer, the patient’s opinion
was more respected in treatment decisions.
Conclusion: Our population-based study suggested that women’s treatment decisions might be shaped by the
information provided by physicians, and that women might request different information from their physicians
based on their preferred treatment options. These results might need to be confirmed in other studies of
treatment decisions.
Background
Patient-physician communication regarding treatment
decisions is a poorly understood area of cancer care. In
recent years, patients have wanted more information
about their diseases and greater involvement in treat-
ment decisions [1,2]. Since shared decision making
(SDM) may result in increased compliance and better
health outcomes [3], it is strongly advocated [4].
Previous studies have explored many aspects of
patient-physician communications, including how they
relate to actual surgical treatment [5-8], the nature of
patient decision-making preferences [9] and what influ-
ences these preferences [10], the fulfillment of patients’
preferred decisional roles [9-11] and their outcomes
(such as satisfaction or regret) [11,12], and the use of
decision aids[13]. In these situations, however, it is little
known whether the physician or patient makes the pri-
mary treatment decision, whether these decisions
depend on disease stage, and whether the provision of
information by the physician on topics such as treat-
ment options and their side effects, associated course of
recovery, and the likelihood of recurrence, affects treat-
ment decisions. Understanding the effects of SDM could
lead to better care of cancer patients [14-16].
We conducted a large population-based survey of
women with breast cancer to test our hypothesis that
patient surgical preferences are influenced by the type of
information provided by their physicians. The study
aimed to determine (1) the prevalence of various com-
ponents of shared decision making, (2) the association
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of SDM with surgical treatment, and (3) whether perso-
nal opinion or information provided by the physician
played a bigger role in the patient’s surgical decision
when patient-physician communication was stratified by
disease stage.
Methods
Study Population
We used 5 hospital-based breast cancer registries in
Korea to identify women who had undergone primary
curative surgery for breast cancer between 1993 and
2002. The registries contained information about tumor
stage, type of surgery, history of cancer therapy, and
other clinical characteristics, such as estrogen and pro-
gesterone receptor status, menopausal status at diagno-
sis, recurrence, and date since surgery. Patients were
considered potentially eligible if they 1) had a diagnosis
of stage 0 to II breast cancer and tumor size ≤ 5 cm, 2)
had no other history of cancer, 3) both breast-conser-
ving surgery and mastectomy were treatment options
and 4) were alive at the time of the survey. From a total
of 10,796 registered women, we identified 8,370 who
were potentially eligible. Of those, we were able to con-
tact 4,126. The most frequent reason for contact failure
was a change of address or telephone number. Of the
women contacted, 30.0% refused to participate. The
most frequent reasons for refusal were that the survey
was inconvenient and that it took too long to complete.
Of the 2,888 women who agreed to participate, most
(80.3%) filled out and returned the questionnaire. After
reviewing the questionnaires for completeness, we were
left with a total study population of 1,893 subjects. The
median follow-up time after surgery was 49 months
(range, 24-133 months).
Data Collection
From May to September 2004, potentially eligible
patients were contacted by telephone, and those who
agreed to participate were sent a questionnaire with
consent forms and a postage-paid return envelope. Sub-
jects who did not return the questionnaire within 1
month received a reminder card and a telephone call.
Multiple attempts were made to contact the remaining
potential subjects by postcard or telephone. The institu-
tional review board of the National Cancer Center
reviewed and approved the protocol.
Measures
The main dependent variable was the type of surgical
treatment, either mastectomy or BCS, obtained from the
clinical database. The principal independent variables were
various patient-reported SDM experiences; patient socio-
demographic variables, including age, education level,
marital status, religion, household income, residential area
(metropolitan vs. rural), size of household, and employ-
ment status; and clinical factors, including comorbidities,
menopausal status, estrogen and progesterone receptor
status, and tumor stage. We measured the SDM as two
dimensions: being informed of alternative treatments and
being patient’s own opinion respected. The following
questions, based on earlier studies, were used to evaluate
SDM [5-10,17]. (1) Was your opinion respected before
your surgical treatment decision? This item was rated on a
5-point Likert scale ranging from “strongly agree” (1) to
“strongly disagree” (5). “Strongly agree” and “agree” were
coded as “yes”, and “neither agree nor disagree”, “disagree”,
and “strongly disagree” were coded as “no”. (2) Did your
doctors provide information on breast surgery options
(e.g., the techniques, consequences, benefits and draw-
backs of each option) before your surgical treatment deci-
sion? (3) Did your doctors provide information on
radiotherapy (e.g., whether it was mandatory, as well as its
consequences, benefits and drawbacks) before your surgi-
cal treatment decision? (4) Did your doctors provide infor-
mation on chemotherapy (e.g., whether it was mandatory,
as well as its consequences, benefits and drawbacks) before
your surgical treatment decision? (5) Did your doctors
provide information on hormone therapy (e.g., whether it
was mandatory, as well as its consequences, benefits and
drawbacks) before your surgical treatment decision? These
questions were posed to all women. The response category
was “yes” or “no”. Feasibility and comprehensibility of the
full survey instrument–including SDM questions, and
socio-demographic and clinical characteristics–were pre-
tested on 15 breast cancer survivors in an outpatient clinic
of the Korean National Cancer Center. Pretesting did not
change the survey instrument, but an independent valida-
tion study was not performed.
Data Analysis
All analyses were performed by weighting the data with
the number of total eligible breast cancer survivors to
ensure that our estimates were representative. To adjust
for the differences observed between respondents and
non-respondents, we used the inverse probability of
response weighting approach described by Robins and
colleagues [18,19]. In this approach, data for each survi-
vor are further weighted according to the reciprocal of
the conditional probability of being a respondent given
all clinical variables (i.e., age and tumor stage at diagno-
sis, tumor size, time since surgery, type of surgery, type
of adjuvant therapy, and hormone receptor status of
tumor). These “adjustment” weights ensure that the
effect of each response is the same in the adjusted
population as in the original eligible population. The
range of weights was 2.07-7.64. We evaluated the bal-
ance on covariates within propensity score quintiles in
the adjusted population to confirm the accuracy of the
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model [20]. We also trimmed the adjustment weights to
reduce the effects of influential observations on the
overall results by minimizing the mean squared error
[21]. These methods control only for observed charac-
teristics; after adjustment, respondents may differ from
non-respondents in unobserved characteristics. Never-
theless, these methods allow for better control of poten-
tial biases between respondents and non-respondents
than methods that include only respondent data.
We computed univariate regressions of the effects of
each of the dichotomously categorized SDM variables and
other potential indicators upon receiving a mastectomy.
We used multiple logistic regression analysis with stepwise
selection to identify the best subset of independent vari-
ables for predicting surgery type. Furthermore, we strati-
fied patients by disease stage (i.e., ranging from stages 0-
IIa to IIb) and performed separate multiple logistic regres-
sion analyses to identify the subset of patients who would
best illustrate the variables influencing surgical decisions
according to disease stage. The significance level for enter-
ing an effect into the multiple logistic regression models
by the stepwise method was .05. Results of multivariate
logistic regression models were expressed as odds ratios
(ORs) relative to subjects’ undergoing a mastectomy. We
considered P < .05 as statistically significant, and all statis-
tical tests were two-sided and performed using SAS Ver-
sion 9.2 (SAS Institute, Inc., Cary, NC).
Results
Compared with patients responding to the question-
naire, a larger proportion of non-respondents were ≥ 65
yr old (62.5% v 57.8%, P < .0001), had advanced (≥ stage
IIb) disease (28.4% v 25.7%, P < .03), underwent surgery
≥ 5 yr ago (54.1% v 36.9%, P < .0001), had received mas-
tectomies (71.2% v 64.4%, P < .0001) and hormonal
therapy (57.2% v 51.5%, P < .0001), had not received
chemotherapy (59.6% v 64.8%, P < .0001), and had
estrogen- (61.0% v 53.5%, P < .0001) or progesterone-
sensitive tumors (59.6% v 49.2%, P < .0001). After
further weighting according to inverse propensity scores
for being a respondent, the respondent population was
made to have distribution on these variables similar to
the distributions in the full population.
Patient Characteristics (Table 1)
Mean patient age at diagnosis was 48.6 years. Table 1
lists their socio-demographic and clinical characteristics.
Patients’ self-reported SDM variables
Overall, most women reported that that their opinions
were respected in surgical treatment decisions (88.5%),
that their doctor had informed them of surgical treat-
Table 1 Demographic and clinical characteristics of
patients who responded to our questionnaire
No. % of patients (n = 1,893)
Variables at the time of initial decision
making
Age at diagnosis, yr
<65 1780 94.0
≥65 113 6.0
Mean (SD) 48.6 (9.4)
Educational attainment
≤high school 1329 70.6
college or higher 554 29.4
Marital status
no spouse 286 15.2
with spouse 1599 84.8
Having a religion
no 282 15.0
yes 1600 85.0
Monthly household income
<US$3000 903 55.5
≥US$3000 723 44.5
Residential area
rural 188 10.0
metropolitan 1696 90.0
No. of family members
<3 1345 71.0
≥3 548 29.0
Menopausal status at diagnosis
pre 1156 61.1
post 737 38.9
Employment status at diagnosis
no 815 44.9
yes 1000 55.1
Stage
0-IIa 1518 80.2
IIb 375 19.8
Estrogen receptor
negative 805 42.5
positive 1088 57.5
Progesterone receptor
negative 844 44.6
positive 1049 55.4
Comorbidity
0 963 50.9
≥1 930 49.1
Type of surgery
mastectomy 1274 67.3
BCS 619 32.7
Received radiotherapy 721 38.1
Received chemotherapy 1190 62.9
Received hormone therapy 1070 56.5
Abbreviations: SD, standard deviation; BCS, breast-conserving surgery
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ment options (89.1%), and on radiotherapy (84.2%), che-
motherapy (78.5%), and hormonal therapy (66.2%).
Factors associated with type of breast cancer surgery–
univariate analyses (Table 2)
In univariate analyses, age, educational level, monthly
household income, residential area, comorbidity, meno-
pausal status, estrogen receptor status, and disease stage
at the time of initial decision making were associated
with type of surgery received (mastectomy versus BCS).
Provision of information on surgery options by the doc-
tors was associated with receiving BCS, whereas being
patient’s opinion respected and doctors’ providing infor-
mation on chemotherapy or hormone therapy were
associated with undergoing a mastectomy.
Factors associated with type of breast cancer
surgery–multivariate logistic regression analysis (Table 3)
Multivariate regression analysis indicated that women
were more likely to undergo mastectomies than BCS if
they were premenopausal, diagnosed with stage IIb
breast cancer, had comorbidities, and were informed on
the use of chemotherapy or hormone therapy by their
doctors. Conversely, women were less likely to undergo
mastectomies if they had estrogen-sensitive tumors, or if
they were informed on breast surgery options by their
doctors.
Factors associated with type of breast cancer surgery
according to disease stage–multivariate logistic
regression analyses (Table 4)
In multivariate logistic regression analysis, factors asso-
ciated with type of treatment varied with tumor stage.
Women with early stage (0-IIa) disease were more likely
to undergo mastectomies than BCS if they had higher
stage disease, or had received information on the use of
chemotherapy or hormone therapy. They were less likely
to undergo mastectomies if they had estrogen-sensitive
tumors or had been informed on breast surgery options.
Women diagnosed with more advanced disease (IIb)
were less likely to undergo mastectomies if they were
more highly educated and were more likely to undergo
mastectomies if they were older, premenopausal, had
more comorbidities, had relied more on their own opi-
nions in making treatment decisions, or had been
informed on the use of hormone therapy by their
doctors.
Discussion
Our study focused on a relatively young and predomi-
nantly pre-menopausal group of women with early-stage
breast cancer who had a relatively high overall rate of
mastectomy. Few studies have explored breast surgery
in this type of population, and there are wide variations
Table 2 Univariate analyses* of factors associated with
type of surgery
Mastectomy (vs. BCS)
N = 1,893
% OR (95% CI)
Predisposing factors at the time of initial
decision making
Age at diagnosis,
<65 64.9 1(referent)
≥65 71.0 1.70(1.32-2.19)
Educational level
high school or less 67.2 1(referent)
college or higher 61.6 0.80(0.72-0.90)
Marital status
no spouse 66.2 1(referent)
married 65.2 0.93(0.81-1.08)
Having a religion
no 65.8 1(referent)
yes 65.2 0.99(0.86-1.14)
Monthly income
<US$3000 68.6 1(referent)
≥US$3000 61.8 0.69(0.63-0.77)
Residential area
rural 70.2 1(referent)
metropolitan area 64.7 0.78(0.65-0.94)
Number of adults living together
<3 65.6 1(referent)
≥3 64.5 0.96(0.85-1.07)
Employment status
unemployed 64.6 1(referent)
employed 65.2 1.07(0.96-1.19)
Comorbidities
none 63.6 1(referent)
≥1 66.8 1.17(1.05-1.29)
Menopausal status
premenopausal 63.5 1(referent)
postmenopausal 68.0 1.17(1.04-1.30)
Estrogen receptor
negative 65.8 1(referent)
positive 62.9 0.88(0.80-0.98)
Progesterone receptor
negative 65.1 1(referent)
positive 65.5 1.00(0.90-1.11)
Stage
0-IIa 61.5 1(referent)
IIb 84.3 3.68(3.11-4.35)
Shared decision making factors
Being patient’s opinion respected in surgical
treatment decision
no 62.7 1(referent)
yes 73.3 1.48(1.24-1.76)
Physician’s giving information
Breast surgery option
no 74.5 1(referent)
yes 63.7 0.59(0.49-0.71)
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in mastectomy rates both within and between different
countries.
Our results suggest that patients might prefer mastect-
omy whereas surgeons might prefer breast conservation.
Recent reports have indicated that when fully informed
about the risks and benefits of various surgery options, a
significant proportion of patients will actively choose
mastectomy [22]. We studied women with stage 0-II
breast cancer to examine the associations between SDM
and treatment decisions according to disease stage and
to determine whether the patient or physician plays the
primary role in determining surgical options. Treatment
decisions made by women with early-stage breast cancer
may be more affected by the surgeon’s providing of
information, whereas decisions made by women with
advanced stage breast cancer may be more dependent
on their own opinions. Although most patients want to
share in the decision making process [1,2], our findings
suggest that treatment decisions are dependent on dis-
ease stage. For example, patients with stage IIb breast
cancer may play a more collaborative role in treatment
decisions than those with early-stage breast cancer, and
a collaborative role may be more associated with mas-
tectomy than BCS. Previous studies [11,23] have
reported that women who reported being most active in
decision making were less likely than more passive
women to undergo BCS, suggesting that women with
more autonomy are more likely to choose a procedure
perceived as more definite [11,23]. This autonomy may
be associated with maximizing patient outcomes [11].
Because patients believed that mastectomy was clinically
superior, those who played a greater role in decision
making were more likely to undergo mastectomy [24].
Patients may prefer mastectomy over BCS because of
concerns about recurrence of disease, recovery from sur-
gery, and side effects of radiation treatment [25].
Women with stage IIb breast cancer may consider their
doctors’ opinions as important factors in decision mak-
ing. However, women uncertain about treatment deci-
sions can ask questions regarding the consequences of
surgery and the possibility of recurrence. In addition,
some surgeons may continue to believe that mastectomy
is clinically superior to BCS, particularly because of the
lower risk of local disease recurrence [25]. The underly-
ing thoughts of both the doctor and the more autono-
mous patient during the decision-making process may
lead to consensus on the appropriate surgical treatment,
and this collaboration may lead to the decision for
mastectomy.
In contrast, better informed early-stage breast cancer
patients tend to choose BCS over mastectomy [26].
Knowledge about the benefits of mastectomy vs. BCS
Table 2: Univariate analyses* of factors associated with
type of surgery (Continued)
Using radiotherapy (ref. no)
no 67.1 1(referent)
yes 65.9 0.95(0.82-1.09)
Using chemotherapy (ref. no)
no 44.0 1(referent)
yes 72.0 3.17(2.79-3.59)
Using hormone therapy (ref. no)
no 49.1 1(referent)
yes 73.4 2.41(2.15-2.69)
Abbreviation: BCS, breast-conserving surgery; CI, confidence interval
* All analyses weighted to account for differential selection by clinical factors
of non-response.
Table 3 Multivariate analysis* of factors associated with surgical treatment
Mastectomy (vs. BCS) N = 1,893 OR* (95% CI)
Predisposing factors
Comorbidities (ref. none) 1.19(1.05-1.34)
Premenopausal (ref. postmenopausal) 1.26(1.11-1.43)
Estrogen receptor (ref: negative) 0.81(0.72-0.91)
Stage, IIb (ref: 0-IIa) 2.55(2.15-3.02)
Shared decision making
Being patient’s opinion respected in treatment decision (ref. no) 1.40(1.14-1.72)
Physician’s giving information
Breast surgery option (ref. no) 0.34(0.27-0.42)
Using chemotherapy (ref. no) 2.57(2.20-3.01)
Using hormone therapy (ref. no) 2.03(1.77-2.32)
Abbreviation: BCS, breast-conserving surgery; CI, confidence interval
* All analyses weighted to account for differential selection by clinical factors of non-response.
** Results of logistic regression with stepwise selection methods, whose covariates were age at diagnosis, educational level, monthly income, residential area,
menopausal status at diagnosis, comorbidity, estrogen receptor, disease stage, patient’s participation in treatment decision, physician’s giving information on
surgery, physician’s giving information on chemotherapy, and physician’s giving information on hormone therapy, all of which were significant in univariate
analyses.
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was the strongest predictor of BCS [27]. Moreover,
we found that clinical factors may be important in treat-
ment decisions made by women with early-stage breast
cancer. Objective factors, such as tumor stage and estro-
gen receptor status, together with adequate information
on breast surgery options, chemotherapy, and hormone
therapy may be associated with treatment decisions.
Due to the workload of medical teams and the lack of
time, it may be difficult for physicians to spend time
with breast cancer patients who have a good prognosis,
in order to reach a decision on treatment. In addition,
being given a choice of treatments may be associated
with increased emotional distress [28]. Because patients
put value on the information regardless of their pre-
ferred decision-making style [1,2], providing sufficient
information may be important to early-stage breast can-
cer patients. We found that collaboration in decision
making may be more feasible among stage IIb than
among early-stage breast cancer patients.
Our finding, that premenopausal women with
advanced disease were more likely to receive mastectomy
and women with hormonally sensitive early stage disease
were more likely to receive BCS, is consistent with other
studies [29,30] and treatment guidelines [31,32].
We found that among women with stage IIb tumors,
those who were older or less educated were more likely
to undergo mastectomy than BCS, in agreement with
previous results [33-35]. One previous study suggested
that better educated and better informed older women
were more likely to undergo BCS [36]. Although under-
going a mastectomy correlates with a patient’s involve-
ment in decision making, mastectomy had been found
to depend on physician recommendations [35]. Physi-
cians may take a greater initiative in the decision mak-
ing process for older patients and those who have less
knowledge about breast cancer [35,37]. Indeed, we
found that breast cancer knowledge was the strongest
predictor of BCS [27]. These observations are consistent
with other reports regarding the influence of age and
education on the decision making process in breast can-
cer patients [38,39].
When making a decision for patients with stage IIb
breast cancer, a surgeon’s sensitivity to patient personal
concerns and anxiety about poor prognosis caused by
comorbidity would likely make patients more willing to
follow the surgeon’s recommendation or to choose mas-
tectomy over BCS.
The association of provision of information regarding
chemotherapy and hormone therapy with a greater like-
lihood of undergoing mastectomy may be due to a
desire for a perceived long-term effect. For patients with
hormone-sensitive tumors, mastectomy followed by
tamoxifen or aromatase inhibitor for postmenopausal
patients may be the safest option [40,41]. Although the
interpretation of information within patients’ social con-
texts may lead to different surgical choices [42] and the
decision-making process gets more complex, the deci-
sion-making pattern may be consistent when physicians
Table 4 Multivariate analyses* of factors associated with surgical treatment according to disease stage
Mastectomy (ref. BCS) OR (95% CI)
Stage 0-IIa** n = 1,518 Stage IIb*** n = 375
Patients’ predisposing factors
Age at diagnosis, ≥65 (ref:< 65) NA 5.63(1.80-7.60)
Comorbidities (ref. none) NA 2.07(1.39-3.09)
College or higher (ref. high school or less) NA 0.60(0.43-0.85)
Premenopausal (ref. Postmenopausal) NA 1.43(1.25-1.63)
Estrogen receptor, positive (ref: negative) 0.79(0.69-0.89) NA
Higher stage**** 1.25(1.13-1.38) NA
Shared decision making
Being patient’s opinion respected in treatment decision (ref. no) NA 5.43(3.48-8.46)
Physician’s giving information
Breast surgery option (ref. no) 0.36(0.28-0.45) NA
Using chemotherapy (ref. no) 2.79(2.37-3.29) NA
Using hormone therapy (ref. no) 1.94(1.67-2.24) 2.69(1.92-3.75)
Abbreviation: BCS, breast-conserving surgery; NA, Not available; CI, confidence interval
*All analyses weighted to account for differential selection by clinical factors of non-response.
** Results of logistic regression with stepwise selection methods whose covariates were age at diagnosis, monthly income, residential area, comorbidity, estrogen
receptor status, disease stage (continuous type), patient’s participation in treatment decision, physician’s giving information on surgery, physician’s giving
information on chemotherapy, and physician’s giving information on hormone therapy, which were significant in univariate analyses.
**The results of logistic regression with stepwise selection methods, whose covariates were age at diagnosis, educational level, marital status, comorbidity,
menopausal status at diagnosis, progesterone receptor status, patient’s participation in treatment decision, physician’s giving information on chemotherapy, and
physician’s giving information on hormone therapy, all of which were significant in univariate analyses.
**** Stage 0, I, and IIa entered into model as continuous type such as 0, 1, and 2 in early stage disease.
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provide their patients with a summary of available treat-
ment options, together with information about the asso-
ciated risks and benefits.
Our study had several limitations. Due to the retro-
spective nature of this study, a considerable amount of
time had elapsed between the treatment and the begin-
ning of the study; therefore, our results may have been
influenced by recall bias. Second, our sample had a low
response rate, with respondents differing from non-
respondents. After weighting the inverse probability of
response, however, the two groups were similar.
Although we made adjustments only for observed char-
acteristics, the method controls for any potential bias
between respondents and non-respondents. Third, we
did not use standard tools to assess information needs
and decision-making strategies. Instead, we designed our
own tool to assess the degree of shared decision making.
The potential flaws in the questionnaire are respected in
some of the observed outcomes. Thus, a validated tool
must be used to assess the topic of this study. Further-
more, we did not include separate SDM questions to
determine if patients were told that the treatment was
mandatory, and whether the patients were informed of
the consequences, benefits and drawbacks of each
option. We presume that patients responded “yes” if
they considered one of or more the sub-portions to be
correct, whereas patients responded “no” if they consid-
ered none of the sub-portions to be correct. It may have
been helpful to determine the physicians’ responses, as
recalled by the patient or the physician. Also the type of
information provided by the physicians would differ for
patients who received BCS versus those who received
mastectomy. Fourth, we assessed SDM by patients’ self-
report and lack of information about physician opinion
or perception of the encounter. However, we measured
an essential part of the SDM process–being informed
on treatment options and accommodation of patients’
values–but measuring multifactorial decision-making
process is difficult [43]. We used self reports because
patient-reported outcome is important and patients may
view SDM differently from health professionals [44]. We
showed that women who report having been respected
in the decision-making process more frequently received
mastectomies than BCS, and women who report having
been very informed about their options for surgery
more frequently received BCS than mastectomies. This
study was a cross-sectional survey and also we did not
obtain any data about the kind of information women
request from their doctors or their preferences prior to
making a decision. We should interpret the set of find-
ings with care, however, as it is possible that physicians
provide more information about surgery to women who
eventually get BCS, and that this might influence
patient’s decision toward BCS, and another finding
could be that women in this population tend to prefer
mastectomy and thus report having their options
respected when get mastectomy.
Conclusions
Our population-based study suggested that women’s
treatment decisions might be shaped by the information
provided by physicians, and that women might request
different information from their physicians based on
their preferred treatment options. These results should
be confirmed in other studies of treatment decisions.
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